Physio-Control to Acquire HeartSine®
Physio-Control has reached an agreement with HeartSine Technologies to acquire the Northern Ireland-based automated external defibrillator (AED) manufacturer, the companies announced today. The two privately held companies recently completed due diligence. Financial details of the transaction are not being released. The combination creates one of the world's largest AED solutions providers.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150914005333/en/
“With Physio-Control and HeartSine now united in our lifesaving missions, we will be able to offer a tremendous range of AED solutions to our global customers and partners,” said Physio-Control CEO Brian Webster. “Sudden cardiac arrest is one of the biggest health care problems in the world and AEDs are a critical part of the solution. The global market for these devices is growing fast and our joint aim is to save more lives with more AEDs in more places.”
The companies share a strong scientific and technical focus with important, often parallel histories. The pioneer of direct current defibrillation, Physio-Control has partnered with leading emergency medical systems since the 1960s and commercialized the first home use AED, the LIFEPAK 100, in 1986. HeartSine’s founder, Professor John Anderson, worked with the pioneer of out-of-hospital mobile coronary care, Dr. Frank Pantridge, in Belfast in the 1960s and 1970s. Professor Anderson was part of the team that developed the world’s first mobile coronary care unit.
“This is very good for HeartSine and our distributors. Our teams share a strong clinical focus, and together we have exciting opportunities ahead for technical, scientific and marketing collaboration,” said HeartSine CEO Declan O’Mahoney. “Most importantly, we have a strong cultural fit and a common mission to prevent unnecessary deaths from sudden cardiac arrest.”
HeartSine’s products include the samaritan® PAD line of public access AEDs, and technologies such as CPR Advisor™, that provides real-time CPR feedback. Physio-Control’s AED products include the LIFEPAK® CR Plus and LIFEPAK 1000, distributed in 104 countries.
LIFEPAK AEDs are designed and manufactured at the company’s Redmond, Washington, headquarters facility and HeartSine products are designed and manufactured in Belfast, Northern Ireland.
Physio-Control, Inc. is headquartered in Redmond, Washington. The company was founded in 1955 and is the world’s leading provider of professional emergency medical response solutions that predict or intervene in life-threatening emergencies. The company’s products include LIFEPAK® monitor/defibrillators and automated external defibrillators, the LIFENET® System, HealthEMS® electronic patient care reporting (ePCR) software, LUCAS® 2 Chest Compression System, TrueCPR™ coaching device, McGrath® MAC EMS video laryngoscope and implementation for PulsePoint mobile bystander response applications. Learn more at www.physio-control.com, or connect via www.facebook.com/physiocontrolinc, https://www.linkedin.com/company/physio-control-inc- Twitter: @PhysioControl
About HeartSine Technologies:
HeartSine Technologies, a world leader in personal and public access defibrillators, advances the deployment of lifesaving defibrillation therapy for the treatment of sudden cardiac arrest in non-traditional areas of care. Designed for use in public areas, the company’s entire line of AED products leverages its proprietary, clinically advanced SCOPE™ technology to optimize the administration of lifesaving treatment. The company’s products include the samaritan® PAD family of AEDs for public access. HeartSine is active in over 70 countries worldwide in a wide range of environments. HeartSine is based in Belfast, Northern Ireland and Newtown, Pennsylvania. To learn how a HeartSine AED can save lives, please visit www.heartsine.com or follow HeartSine on Facebook and Twitter.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Group Vivendi Africa Deploys Netcracker OSS to Enhance Service Management as it Expands Across the Continent12.12.2017 16:07 | Pressemelding
Netcracker Technology announced today that its OSS suite was selected and deployed to support the long-term growth strategy of Group Vivendi Africa (GVA). GVA is a newly formed affiliate of the French-based multinational conglomerate Vivendi with the goal to deploy and operate a fiber network across Africa. Netcracker's OSS will be used as a consolidated solution to identify service availability across GVA's operating countries and then fulfill and provision those services to customers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005937/en/ Netcracker's highly productized, out-of-the-box applications enabled the OSS suite to be deployed in seven months, meeting GVA's demand to leverage an integrated service fulfillment and inventory solution that could satisfy its long-term growth expectations, as well as s
Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program12.12.2017 15:23 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/ Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire) This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s
Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 14:00 | Pressemelding
Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid
Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 13:33 | Pressemelding
Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for
CTS Engines Announces Senior Management Hire12.12.2017 13:00 | Pressemelding
CTS Engines, the global leader for mature jet engine maintenance, announced today that it had hired Diane E. Cavuoto as Senior Vice President, Supply Chain, in an effort to continue to provide its customers with outstanding engine overhaul services. Ms. Cavuoto will be based in CTS’s Ft. Lauderdale headquarters and will report directly to Vesa Paukkeri, CTS’s President and Chief Operating Officer. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005050/en/ Diane E. Cavuoto, Senior Vice President, Supply Chain, for CTS Engines (Photo: Business Wire) Ms. Cavuoto, most recently Vice President, Strategic Sourcing at Honeywell International, brings years of supply chain management experience to CTS. In her prior role at Honeywell, Ms. Cavuoto managed a global commodity team of 150 employees managing $4
MIPI Alliance Opens Access to its MIPI I3C Sensor Interface Specification12.12.2017 13:00 | Pressemelding
The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced it is opening access to its sensor interface specification, MIPI I3C. Starting today, all companies, including those not currently members of MIPI Alliance, may access the MIPI I3C v1.0 specification so they may evaluate the incorporation of the specification into their sensor integration plans and design applications. “MIPI I3C provides a welcome update to the I2C technology that has been widely adopted over the past 35 years. Extending access provides an opportunity to spur innovation and help other industries beyond mobile," said Joel Huloux, chairman of MIPI Alliance. "It helps MIPI members as well, because it supports greater adoption and interoperability, strengthens the ecosystem and provides for a richer
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom